| 摘要 |
The present invention relates to the use of at least one antibody, or a functional fragment thereof, capable of binding to the CXCR4 protein and thus of inhibiting tumour growth, for the preparation of a medicament for use in the treatment of cancer. The invention also relates to a composition for treating cancer, comprising, as active ingredient, at least one anti-CXCR4 antibody, or a functional fragment thereof, capable of binding to the CXCR4 protein and/or of inhibiting the angiogenic and/or proliferative activity thereof. More particularly, said antibodies consist of the MAB 173 antibody. |
